The RD Fund (Retinal Degeneration Fund) – the venture arm of the Foundation Fighting Blindness – has invested in a USD115 million syndicated Series B round for SalioGen Therapeutics to support the company’s preclinical research into novel genetic medicines for inherited retinal disorders.
The RD Fund (Retinal Degeneration Fund) – the venture arm of the Foundation Fighting Blindness – has invested in a USD115 million syndicated Series B round for SalioGen Therapeutics to support the company’s preclinical research into novel genetic medicines for inherited retinal disorders.
SalioGen is a privately held biotechnology company developing Gene CodingTM, a new category of genetic medicine.
SalioGen’s Gene Coding platform works by adding a new genomic code to turn on, off, or modify function of new or existing genes. Gene Coding is accomplished by SalioGen’s Exact DNA Integration TechnologyTM (EDITTM), which is based on mammal-derived genome engineering enzymes called SaliogaseTM. Saliogase seamlessly inserts new DNA of any size into precise, defined genomic locations.
The Series B financing enables SalioGen to continue building out the Gene Coding platform, expand the company’s team, establish manufacturing and automation capabilities critical for Gene Coding and accelerate the advancement of its preclinical programmes.
